Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001576885-25-000057
Filing Date
2025-04-23
Accepted
2025-04-23 16:23:13
Documents
17
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A abos-20250422.htm   iXBRL DEF 14A 513775
3 abos-20250422_g1.jpg GRAPHIC 27597
4 abos-20250422_g2.jpg GRAPHIC 7937
5 abos-20250422_g3.jpg GRAPHIC 3176
6 abos-20250422_g4.jpg GRAPHIC 196435
7 abos-20250422_g5.jpg GRAPHIC 105116
  Complete submission text file 0001576885-25-000057.txt   1657442

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20250422.xsd EX-101.SCH 930
19 EXTRACTED XBRL INSTANCE DOCUMENT abos-20250422_htm.xml XML 3179
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40551 | Film No.: 25861823
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)